



00-000000000



182172

**CAREFIRST - MD EXCHANGE 5T
Lotronex (HMF)**

This fax machine is located in a secure location as required by HIPAA regulations. Fax complete signed and dated forms to CVS/Caremark at 888-836-0730. Please contact CVS/Caremark at 855-582-2022 with questions regarding the prior authorization process. When conditions are met, we will authorize the coverage of Lotronex (HMF).

Patient Name: _____ **Date:** 11/28/2023
Patient ID: _____ **Patient Date Of Birth:** _____
Patient Group No: _____ **Patient Phone:** _____ **Physician Name:** _____
NPI#: _____ **Specialty:** _____
Physician Office Telephone: _____
Physician Office Address: _____

Drug Name (select from list of drugs shown)

Alosetron

Quantity: _____ **Frequency:** _____ **Strength:** _____

Route of Administration: _____ **Expected Length of Therapy:** _____

Diagnosis: _____ **ICD Code:** _____

Comments: _____

Please check the appropriate answer for each applicable question.

- | | | |
|--|----------------------------|----------------------------|
| 1. Is the requested drug being prescribed for a biological female or a person that self-identifies as a female with a diagnosis of severe diarrhea-predominant irritable bowel syndrome (IBS)? | Y <input type="checkbox"/> | N <input type="checkbox"/> |
| 2. Has the patient experienced chronic irritable bowel syndrome (IBS) symptoms lasting at least 6 months? | Y <input type="checkbox"/> | N <input type="checkbox"/> |
| 3. Have gastrointestinal tract abnormalities been ruled out? | Y <input type="checkbox"/> | N <input type="checkbox"/> |
| 4. Has the patient had an inadequate response to conventional therapy? | Y <input type="checkbox"/> | N <input type="checkbox"/> |

I attest that the medication requested is medically necessary for this patient. I further attest that the information provided is accurate and true, and that the documentation supporting this information is available for review if requested by the claims processor, the health plan sponsor, or, if applicable a state or federal regulatory agency.

Prescriber (Or Authorized) Signature and Date

Effective July 1, 2015, Maryland law will require providers to submit pharmaceutical preauthorization requests electronically. To use ePA, either contact your electronic health record vendor or visit www.covermymeds.com/epa/caremark